Project Grant HT94252410552
Award Date
6/15/24
Completion Date
6/14/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The federal Project Grant award, totaling $384,342.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute For Cancer Research, a non-profit organization in New York, NY. The award, effective June 15, 2024 through June 14, 2027, supports the development of generalizable and reliable AI for early detection of melanoma. Through this funding, the Sloan-Kettering Institute For Cancer Research will...
The Sloan-Kettering Institute for Cancer Research was awarded a $906,740 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an application for following images of nevi (moles) to detect melanoma. The project will be conducted over a 3-year period from August 1, 2023 to July 31, 2026. Through this federal grant, the Sloan-Kettering Institute, a non-profit research organization, will focus on innovative and impactful...
Sloan-Kettering Institute For Cancer Research was awarded a $845,789 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2023 to June 30, 2026. The grant will support research to discover biomarkers and address outcome disparities for prostate cancer through exploiting real-world clinical genomic data. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise...
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
This $176,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the Sloan-Kettering Institute for Cancer Research to investigate the interactions of mitochondrially encoded complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to further the understanding of cancer biology and potential therapeutic approaches, with a focus on conditions...
The Sloan-Kettering Institute for Cancer Research was awarded a $923,999 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the effects of tobacco smoking on African American patients with lung cancer. The award will support a multi-year research initiative from July 1, 2024 to June 30, 2027. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute for...
The Project Grant award of $352,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the Sloan-Kettering Institute for Cancer Research in augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor for the treatment of glioblastoma. The award, with a performance period from September 1, 2025 to August 31, 2027, will enable Sloan-Kettering to conduct advanced biomedical research focused on transforming healthcare for...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $700,611 to the Sloan-Kettering Institute for Cancer Research to conduct a practical randomized controlled trial of artificial intelligence (AI) for improving melanoma diagnosis. The key objectives are to: 1) assess clinician perceptions and barriers to adopting AI technology, and develop a mitigation framework to overcome these barriers; and...